###begin article-title 0
Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 8 11 8 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">LEP</bold>
###xml 152 156 152 156 <bold xmlns:xlink="http://www.w3.org/1999/xlink">LEPR</bold>
###xml 210 214 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 210 214 210 214 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 218 223 218 223 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
Leptin (LEP) has been consistently associated with angiogenesis and tumor growth. Leptin exerts its physiological action through its specific receptor (LEPR). We have investigated whether genetic variations in LEP and LEPR have implications for susceptibility to and prognosis in breast carcinoma.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 108 112 108 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 116 121 116 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
We used the polymerase chain reaction and restriction enzyme digestion to characterize the variation of the LEP and LEPR genes in 308 unrelated Tunisian patients with breast carcinoma and 222 healthy control subjects. Associations of the clinicopathologic parameters and these genetic markers with the rates of the breast carcinoma-specific overall survival (OVS) and the disease free survival (DFS) were assessed using univariate and multivariate analyses.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 84 99 84 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) GA </italic>
###xml 84 99 84 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) GA </italic></bold>
###xml 111 113 111 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 136 151 136 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) AA </italic>
###xml 136 151 136 151 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) AA </italic></bold>
###xml 163 165 163 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 252 263 252 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223QR </italic>
###xml 252 263 252 263 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223QR </italic></bold>
###xml 284 286 284 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 309 320 309 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223RR </italic>
###xml 309 320 309 320 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223RR </italic></bold>
###xml 341 343 341 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
A significantly increased risk of breast carcinoma was associated with heterozygous LEP (-2548) GA (OR = 1.45; P = 0.04) and homozygous LEP (-2548) AA (OR = 3.17; P = 0.001) variants. A highly significant association was found between the heterozygous LEPR 223QR genotype (OR = 1.68; P = 0.007) or homozygous LEPR 223RR genotype (OR = 2.26; P = 0.001) and breast carcinoma.
###end p 7
###begin p 8
###xml 30 44 30 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 30 44 30 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 175 185 175 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223R </italic>
###xml 175 185 175 185 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223R </italic></bold>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
Moreover, the presence of the LEP (-2548) A allele showed a significant association with decreased disease-free survival in breast carcinoma patients, and the presence of the LEPR 223R allele showed a significant association with decreased overall survival.
###end p 8
###begin title 9
Conclusion
###end title 9
###begin p 10
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 48 52 48 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 56 61 56 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
Our results indicated that the polymorphisms in LEP and LEPR genes are associated with increased breast cancer risk as well as disease progress, supporting our hypothesis for leptin involvement in cancer pathogenesis.
###end p 10
###begin title 11
Background
###end title 11
###begin p 12
###xml 110 111 110 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 329 330 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 331 332 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 759 760 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 60 65 <span type="species:ncbi:9606">women</span>
Breast cancer is the most frequently diagnosed cancer among women, with a lifetime incidence of about 10-13% [1,2] but its etiology is still not fully understood. Besides, age at menarche and menopause, diet, reproductive history, estrogen administration and genetic factors have been suggested as risk factor for breast cancer [3-7]. Germline mutations in dominant, highly penetrant susceptibility genes, such as BRCA1 and BRCA2, have been identified to be responsible for less than 10% of breast carcinoma. In addition, low-penetrance genes, that also increase susceptibility to breast cancer, have been suggested. For instance, candidate low-penetrance breast cancer susceptibility genes include those involved in the complex mechanisms of carcinogenesis [8].
###end p 12
###begin p 13
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 168 173 <span type="species:ncbi:9606">women</span>
Higher body weight appears to play a role in the development of breast/mammary tumors. Obesity has been identified as a risk factor for breast cancer in postmenopausal women [9-11], and higher body weight is associated with increased incidence of both spontaneous and chemically induced mammary tumors in rodents [12-15].
###end p 13
###begin p 14
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 367 372 <span type="species:ncbi:9606">human</span>
###xml 390 393 <span type="species:ncbi:10116">rat</span>
Leptin, a 16 kDa polypeptide hormone produced predominantly by white adipose tissue [16], plays an important role in body weight homeostasis through effects on food intake and energy expenditure [17,18]. In addition to the regulation of body weight, leptin also influences hematopoiesis, reproduction, angiogenesis, and immune processes [19-22]. The leptin gene, the human homologue of the rat obese gene (OB), has been cloned and sequenced by Zhang et al. [16]. It is located on chromosome 7q31.3 [23,24] and expresses a 4.5 kb mRNA in adipose tissue [16,25].
###end p 14
###begin p 15
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
Leptin exerts its physiological action through the leptin receptor (LEPR), a member of the class 1 cytokine receptor family. LEPR was initially identified in the brain, which explains the negative feedback mechanism of controlling food intake and body weight [26]. However, further studies have demonstrated that LEPR is also expressed in many other tissues and cells, including placenta, pancreas, hematopoietic cells, liver, lung and gastric mucosal cells [27-32].
###end p 15
###begin p 16
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 10 15 10 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 66 71 66 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human LEPR gene is on chromosome 1. Six isoforms derived from LEPR transcription have been identified, and a long isoform, LEPR-b, is reported to be responsible for signal transduction [33].
###end p 16
###begin p 17
###xml 108 117 108 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 147 156 147 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 160 168 160 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 14 19 <span type="species:ncbi:9606">human</span>
In animal and human cell lines, leptin and leptin receptors have also been clearly associated with enhanced in vitro tumor proliferation and/or to in vitro and in vivo promotion of angiogenesis. These effects have been documented in embryonic cells [34], adipocytes [35], glia [36], endothelial cells [37], hematopoietic cells [38], and in benign and malignant epithelial breast cells [39-42], kidney, colon [43,44], liver [45], and pancreas [46].
###end p 17
###begin p 18
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
In breast cancer tissue, it was shown that leptin and leptin receptor are both expressed and that they act to favour cancer proliferation and metastasis [47,48]. Controversial results have been reported regarding the detection of serum leptin levels in breast cancer patients [49,50]. However, the most recent reports indicate that higher leptin serum levels are associated with advanced stage breast cancer [51,52].
###end p 18
###begin p 19
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 61 65 61 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 69 74 69 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 83 85 83 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G </italic>
###xml 83 85 83 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>G </italic></bold>
###xml 88 90 88 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 88 90 88 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A </italic></bold>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 158 162 158 162 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 194 196 194 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 194 196 194 196 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A </italic></bold>
###xml 199 201 199 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G </italic>
###xml 199 201 199 201 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>G </italic></bold>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 274 279 274 279 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 346 351 346 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 346 351 346 351 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
In humans, several polymorphisms have been identified in the LEP and LEPR genes: a G to A substitution at nt -2548 upstream of the ATG start site [53] in the LEP gene 5' promoter region, and an A to G substitution at nt 668 from the start codon 223 in exon 6 (Q223R) of the LEPR gene coding for the extracellular region common to all isoforms of LEPR [54].
###end p 19
###begin p 20
###xml 4 6 4 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G </italic>
###xml 4 6 4 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>G </italic></bold>
###xml 9 11 9 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 9 11 9 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A </italic></bold>
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 40 44 40 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 149 154 149 154 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
The G to A substitution at -2548 of the LEP gene was associated with leptin production [55,56]. The glutamine to arginine substitution occurs on the LEPR gene within the first of two putative leptin-binding regions and may be associated with impaired signalling capacity of the leptin receptor [57].
###end p 20
###begin p 21
###xml 109 119 109 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223R </italic>
###xml 109 119 109 119 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223R </italic></bold>
###xml 122 136 122 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 122 136 122 136 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 157 169 157 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) </italic>
###xml 157 169 157 169 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) </italic></bold>
###xml 169 171 169 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 169 171 169 171 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A </italic></bold>
###xml 317 331 317 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) G </italic>
###xml 317 331 317 331 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) G </italic></bold>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
Enhanced gene expression and increased circulating leptin levels have been reported in subjects carrying the LEPR 223R or LEP (-2548) A alleles [55-57]. The LEP (-2548) A allele has also been associated with a two-fold increase of leptin secretion adipocytes when compared to secretion by adipocytes bearing only the LEP (-2548) G allele [56].
###end p 21
###begin p 22
###xml 241 257 241 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) G/A </italic>
###xml 241 257 241 257 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) G/A </italic></bold>
###xml 261 272 261 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR Q223R </italic>
###xml 261 272 261 272 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR Q223R </italic></bold>
We hypothesize that these leptin and leptin receptor polymorphisms associated with higher leptin serum levels and overexpression of leptin in adipocytes, favour breast cancer development and aggressiveness. In the present study, we analysed LEP (-2548) G/A and LEPR Q223R genotypes in a series of breast cancer cases and normal controls.
###end p 22
###begin title 23
Methods
###end title 23
###begin title 24
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 24
###begin p 25
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 39 43 39 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 47 52 47 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
The gene and allele frequencies of the LEP and LEPR genes were determined in a group of 222 control subjects and 308 patients with breast carcinoma. Controls and patients were selected from the same population living in the middle coast of Tunisia. Both the control and patients groups include unrelated subjects.
###end p 25
###begin p 26
###xml 8 15 <span type="species:ncbi:9606">patient</span>
Data on patient, tumour and treatment characteristics at the study entry for each subject were collected from the department of Radiation Oncology and Medical Oncology of Sousse Hospital (Sousse, Tunisia) between 1996 and 2003. They were selected consecutively whenever practically feasible.
###end p 26
###begin p 27
###xml 460 461 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 618 620 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 723 724 721 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
All patients included in this study had primary breast carcinoma, with unilateral breast tumours and with no family history for the disease. The diagnosis of cancer was confirmed by histopathology analyses. The patients (n = 308) had a mean age of 50 +/- 24 years. The median of follow-up was 36 months (range, 1-120 months). At time of analysis, 66 patients experienced recurrence (local or distant). Among them, 35 died from breast carcinoma (54.5 %). Table 1 shows the treatment description of all patients. A detailed description of the clinicopathologic characteristic of this cohort has been reported elsewhere [58] and data on tumor size at diagnosis, nodal status and histologic grade are briefly included in Table 3.
###end p 27
###begin p 28
###xml 8 13 <span type="species:ncbi:9606">women</span>
Healthy women (n = 222) having a mean age of 48 +/- 14 years, were blood donors with no evidence of any personal or family history of cancer (or other serious illness). Samples from healthy controls were collected consecutively between 1996 and 2003. Both cases and controls were informed and gave written consent to participate in the study and to allow their biological samples to be genetically analyzed. Approval for the study was given by the National Ethical Committee.
###end p 28
###begin title 29
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients treated by chemotherapy as a primary treatment
###end title 29
###begin p 30
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
Among the 308 patients, 121 had chemotherapy as an anticancer primary treatment. The chemotherapy induction was based in all cases on the combination of cyclophosphamide (100%), 5-fluorouracil (100%) with adriamycin (34%) or epirubicin (52%) or methotrexate (14%). For neoadjuvant treatment, patients received four or six chemotherapy cycles before surgery. The clinical response to induction chemotherapy for all cases was defined according to the following criteria: complete response when regression of the tumour was total, partial response when reduction of tumour size was greater then 50% and poor response when the reduction of tumour size was less then 50% (tumour size was measured by the bidimensional product of the horizontal and vertical dimensions).
###end p 30
###begin title 31
Genomic DNA extraction
###end title 31
###begin p 32
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 189 190 189 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 193 194 193 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 265 266 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 551 552 538 539 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Genomic DNA was extracted from peripheral blood leukocytes by a salting procedure [59]. Briefly, 10 ml of blood was mixed with triton lysis buffer (0.32M sucrose, 1% Triton X-100, 5 mM MgCl2, H2O, 10 mM Tris-HCl, PH 7.5). Leukocytes were spun down and washed with H2O. The pellet was incubated with proteinase K at 56degreesC and subsequently salted out at 4degreesC using a substrate NaCl solution. Precipated proteins were removed by centrifugation. The DNA in supernatant fluid was precipated with ethanol. The DNA pellet was dissolved in 400 mul H2O.
###end p 32
###begin title 33
Polymorphism analysis of the -2548 G/A LEP gene
###end title 33
###begin p 34
###xml 4 14 4 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-2548 G/A </italic>
###xml 4 14 4 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>-2548 G/A </italic></bold>
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 34 38 34 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 384 385 382 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The -2548 G/A polymorphism of the LEP gene was analysed by restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR). This method was carried out by PCR amplification using forward primer 5'-TTTCTGTAATTTTCCCGTGAG-3' and reverse primer 5'-AAAGCAAAGACAGGCATAAAAA-3' in a 25 mul reaction mixture containing genomic DNA samples (100 ng), 200 mumol/L dNTPs, 1.5 mM MgCl2, 1 X Taq polymerase buffer, 50 pmol of each primer, and 0.5 unit of Taq DNA polymerase (Amersham, Paris, France). Reaction conditions used with the thermal cycler (Biometra, GOttingem, Germany) were as follows: an initial incubation at 94degreesC for 5 minutes followed by 30 cycles of incubation at 94degreesC for 45 seconds, 52degreesC for 45 seconds and 72degreesC for 45 seconds with a final extension at 72degreesC for 7 minutes. The PCR product (242 bp) was verified by DNA sequencing.
###end p 34
###begin p 35
###xml 62 65 62 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cfo</italic>
###xml 252 253 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 252 253 246 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>G</italic></bold>
###xml 267 268 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 267 268 261 262 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic></bold>
###xml 277 280 271 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cfo</italic>
The amplified products were digested with the addition of 2 U CfoI for 3 hours at 37degreesC. The digested samples were separated by electrophoresis through a 2% agarose gels and stained with ethidium bromide. The polymorphism was defined by presence (G) or absence (A) of the CfoI restriction site. To assess reliability of genotyping we performed double sampling RFLP-PCR in more than 10% of the samples and found no differences.
###end p 35
###begin title 36
Polymorphism analysis of the LEPR gene
###end title 36
###begin p 37
###xml 48 50 48 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 99 102 99 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 127 129 127 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 127 129 127 129 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A </italic></bold>
###xml 132 134 132 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G </italic>
###xml 132 134 132 134 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>G </italic></bold>
###xml 174 179 174 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 174 179 174 179 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 455 456 455 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Based on the method described by Gotoda et al. [54], a PCR followed by digestion with endonuclease MspI was used to detect the A to G transition polymorphism at codon 223 of LEPR gene. Two sequence specific oligonucleotides primers were used for the polymerase chain reaction (PCR): the 3' primer 5'-AAACTCAACGACACTCTCCTT- 3' and 5' primer 5'-TGAACTGACATTAGAGGTGAC- 3'. PCR was performed by using 100 ng genomic DNA as template, 0.01 mM dNTPs, 1.5 mM MgCl2, 1 X Taq polymerase buffer, 0.75muM of each primer and 0.5 U of Taq DNA polymerase in a total reaction of 25 mul. Reaction conditions used with the thermal cycler were as follows: 94degreesC for 5 min followed by 35 cycles at 94degreesC for 30 seconds, 52degreesC for 45 seconds and 72degreesC for 45 seconds. A final extension step was carried out at 72degreesC for 5 min.
###end p 37
###begin p 38
###xml 245 248 245 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 360 363 360 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 486 490 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR</italic>
###xml 486 490 486 490 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR</italic></bold>
###xml 544 547 544 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 574 579 574 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">223Q </italic>
###xml 574 579 574 579 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>223Q </italic></bold>
###xml 583 587 583 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">223R</italic>
###xml 583 587 583 587 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>223R</italic></bold>
The PCR products (80 bp) were electrophoresed on a 3% agarose gel containing ethidium bromide to monitor amplification and possible contamination. The PCR product (80 bp) was verified by DNA sequencing. The 80 bp PCR products were digested with MspI and analysed on 4% (3:1 Nusieve: Normal) agarose gels because of the small DNA products size. The presence of MspI site was indicated by the cleavage of the amplified product into two fragments of 57 and 23 bp. The two allelic forms of LEPR, corresponding to the absence or the presence of the MspI site, are referred to as 223Q and 223R, respectively.
###end p 38
###begin title 39
Statistical analyses
###end title 39
###begin p 40
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 26 30 26 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 34 39 34 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 246 253 246 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 267 271 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 267 271 267 271 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 274 279 274 279 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 95 102 <span type="species:ncbi:9606">patient</span>
The allele frequencies of LEP and LEPR were tested for the Hardy-Weinberg equilibrium for both patient and control groups using the chi-square test. The same test was used to evaluate for significant association between disease (breast carcinoma versus controls) and LEP or LEPR genotypes or alleles.
###end p 40
###begin p 41
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 256 263 <span type="species:ncbi:9606">patient</span>
Disease-free survival (DFS) was defined as the time from the date of diagnosis to the first local or distant recurrence or to last contact. Breast carcinoma-specific overall survival (OVS) was defined as the time from the date of diagnosis to death if the patient died from breast carcinoma or to last contact. Six-year survival rates were estimated, and survival curves were plotted according to Kaplan and Meier [60]. The differences between groups were calculated by the log-rank test [61].
###end p 41
###begin p 42
###xml 81 88 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 166 173 164 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 200 201 198 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 203 205 201 203 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 205 212 203 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 213 214 211 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 216 217 214 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
Clinicopathological parameters were dichotomised as follows: nodal status (>/= 1 versus no positive lymph node), SBR (Scarff, Bloom and Richardson) tumour grade (1-2 versus 3), clinical tumour size (T1-T2 versus T3-T4).
###end p 42
###begin p 43
Statistics were performed using SEM-STATISTIQUES software (centre Jean Perrin, Clermont-Ferrand, France).
###end p 43
###begin title 44
Results
###end title 44
###begin title 45
Polymorphisms in the LEP and LEPR genes as risk factor for breast carcinoma
###end title 45
###begin p 46
###xml 57 73 57 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) G/A </italic>
###xml 57 73 57 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) G/A </italic></bold>
###xml 77 88 77 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR Q223R </italic>
###xml 77 88 77 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR Q223R </italic></bold>
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 217 221 217 221 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 225 230 225 230 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 307 309 307 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 317 319 317 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 326 328 326 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 336 338 336 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 279 286 <span type="species:ncbi:9606">patient</span>
The genotype distribution and allele frequencies for the LEP (-2548) G/A and LEPR Q223R polymorphisms in all patients with breast carcinoma and in the control group are presented in Table 2. The allele frequencies of LEP and LEPR genes were in Hardy-Weinberg equilibrium in both patient and control groups (P = 0.55, P = 0.7; P = 0.17, P = 0.376 respectively).
###end p 46
###begin p 47
###xml 75 90 75 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) AA </italic>
###xml 75 90 75 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) AA </italic></bold>
###xml 124 126 124 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 151 166 151 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) GA </italic>
###xml 151 166 151 166 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) GA </italic></bold>
###xml 187 189 187 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 202 216 202 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 202 216 202 216 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 321 325 321 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P = </italic>
###xml 265 272 <span type="species:ncbi:9606">patient</span>
A significantly higher risk for breast cancer was observed for carriers of LEP (-2548) AA genotype (Odds Ratio (OR) = 3.17; P = 0.001) and carriers of LEP (-2548) GA genotype (OR = 1.45; P = 0.04). The LEP (-2548) A allele frequency was significantly higher in the patient group compared to the control group (OR = 1.55; P = 0.001).
###end p 47
###begin p 48
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 29 34 29 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">223R </italic>
###xml 34 39 34 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>223R </italic></bold>
###xml 125 127 125 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 168 179 168 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223QR </italic>
###xml 168 179 168 179 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223QR </italic></bold>
###xml 343 345 343 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 387 399 387 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223 RR </italic>
###xml 387 399 387 399 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223 RR </italic></bold>
###xml 469 471 469 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 613 627 613 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 613 627 613 627 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 631 641 631 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223R </italic>
###xml 631 641 631 641 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223R </italic></bold>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 196 203 <span type="species:ncbi:9606">patient</span>
###xml 295 302 <span type="species:ncbi:9606">patient</span>
###xml 416 423 <span type="species:ncbi:9606">patient</span>
The allelic frequency of the LEPR 223R was 0.446 in patients with breast carcinoma and 0.338 in control subjects (OR = 1.57; P = 0.0003). The frequency of heterozygous LEPR 223QR was 0.471 in the patient group and 0.405 in the control population resulting in a significantly increased OR in the patient group bearing this genotype (OR = 1.68; P = 0.007). The frequency of the homozygous LEPR 223 RR was 0.211 in the patient group and only 0.135 in controls (OR = 2.26; P = 0.001). These data, taken together, suggest that an increased risk of developing breast carcinoma is associated with the inheritance of the LEP (-2548) A and LEPR 223R alleles in a dose-dependant manner.
###end p 48
###begin p 49
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 141 145 141 145 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 149 154 149 154 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
When we stratified the patients according to the menopause status (190 pre-menopausal and 118 post-menopausal) no significant changes in the LEP and LEPR genotype distributions were seen in breast carcinoma subgroups (data not shown).
###end p 49
###begin title 50
Prognostic significance of polymorphism in LEP and LEPR genes
###end title 50
###begin p 51
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 35 39 35 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 43 48 43 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
Table 3 shows the distributions of LEP and LEPR polymorphisms according to the clinic-pathologic indices of breast carcinoma severity.
###end p 51
###begin p 52
###xml 229 243 229 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 229 243 229 243 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 311 313 311 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
We stratified patients according to tumor size in two subgroups. The first group includes tumor size less than 5 cm (T1-T2) and the second group includes patients with locally advanced breast cancer (T3-T4). The frequency of the LEP (-2548) A allele was significantly higher in patients with larger tumor size (P = 0.05). No association was found with the other clinic-pathologic parameters.
###end p 52
###begin p 53
###xml 60 74 60 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 60 74 60 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
When we tested the relationship between the presence of the LEP (-2548) A allele in all the 308 patients and the survival (OVS and DFS), significant differences were observed between the DFS Kaplan-Meier survival curves for the different polymorphisms.
###end p 53
###begin p 54
###xml 19 20 19 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 121 135 121 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 121 135 121 135 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 246 260 246 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 246 260 246 260 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 374 388 374 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) G </italic>
###xml 374 388 374 388 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) G </italic></bold>
###xml 411 413 411 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 89 96 <span type="species:ncbi:9606">patient</span>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
As shown in figure 1, the breast carcinoma specific DFS was significantly shorter in the patient population carrying the LEP (-2548) A allele. The estimated 3- and 6- year breast carcinoma specific DFS rates in the group of patients carrying the LEP (-2548) A allele were, respectively, 85.29 % and 60.29 % versus the DFS rates of 95.59 % and 79.41 % for those carrying the LEP (-2548) G allele (log rank test, P < 0.03). No statistical difference in overall survival between both groups of patients was observed.
###end p 54
###begin p 55
###xml 94 104 94 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223R </italic>
###xml 94 104 94 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223R </italic></bold>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 210 220 210 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223R </italic>
###xml 210 220 210 220 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223R </italic></bold>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">223Q </italic>
###xml 310 315 310 315 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>223Q </italic></bold>
###xml 338 340 338 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 395 405 395 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223R </italic>
###xml 395 405 395 405 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223R </italic></bold>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 444 452 <span type="species:ncbi:9606">patients</span>
The breast carcinoma specific OVS was significantly shorter in the group of patients carrying LEPR 223R allele (Fig. 2). The estimated 3- and 6- year breast carcinoma OVS rate in the group of patients carrying LEPR 223R allele were, respectively, 86.76 % and 75 % versus 98.5 and 97.06% for those carrying the 223Q allele (log rank test, P < 0.01). In contrast, no association was found between LEPR 223R and the DFS rate in this population of patients with breast carcinoma.
###end p 55
###begin p 56
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 68 72 68 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 76 81 76 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
Multivariate analyses were undertaken to evaluate the importance of LEP and LEPR markers in the risk of the recurrence and death compared with the clinicopathologic parameters. Introducing the genetic and the clinicopathologic parameters bearing prognostic significance has tested the Cox model. No genetic and clinicopathologic parameters were selected for OVS and DFS.
###end p 56
###begin title 57
Discussion
###end title 57
###begin p 58
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 233 238 <span type="species:ncbi:9606">women</span>
Leptin is a cytokine produced mainly by adipose tissue. Leptin has recently been reported to stimulate the proliferation of various cell types and is considered to be a new growth factor. Hyperleptinemia is a common feature of obese women who have a risk of breast cancer higher than those with normal weight and epidemiologic studies have suggested a positive correlation between obesity and breast cancer risk [62].
###end p 58
###begin p 59
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 346 350 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 346 350 346 350 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 371 376 371 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 371 376 371 376 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 152 157 <span type="species:ncbi:9606">human</span>
In addition, recent studies indicate that leptin is a mitogenic [63], as well as pro-angiogenic factor in various cell models. New data documented that human breast cancer cell lines and breast tumors may express leptin and leptin receptors [40,42,47,48]. These characteristics of leptin prompted us to evaluate whether genetic variations of the LEP gene promoter and/or LEPR exon 6 affect susceptibility to and prognosis of breast cancer.
###end p 59
###begin p 60
###xml 156 170 156 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 156 170 156 170 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 205 219 205 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 205 219 205 219 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 286 288 286 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 338 352 338 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) G </italic>
###xml 338 352 338 352 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) G </italic></bold>
###xml 364 379 364 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) GA </italic>
###xml 364 379 364 379 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) GA </italic></bold>
###xml 456 458 456 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
The present case/control study showed a substantially increased risk of breast carcinoma associated in a dose-dependent manner, with the inheritance of the LEP (-2548) A allele. Individuals homozygous for LEP (-2548) A have more than 3-fold risk to develop breast carcinoma (OR = 3.17; P = 0.001) compared with individuals homozygous for LEP (-2548) G allele. The LEP (-2548) GA heterozygotes patients have an intermediate risk for this cancer (OR = 1.45; P = 0.04).
###end p 60
###begin p 61
###xml 42 53 42 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR Q223R </italic>
###xml 42 53 42 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR Q223R </italic></bold>
###xml 141 152 141 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223QR </italic>
###xml 141 152 141 152 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223QR </italic></bold>
###xml 156 159 156 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RR </italic>
###xml 156 159 156 159 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>RR </italic></bold>
###xml 205 215 205 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223R </italic>
###xml 205 215 205 215 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223R </italic></bold>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
Comparison of genotype frequencies of the LEPR Q223R alleles in patients with breast carcinoma and control subjects indicated an increase of LEPR 223QR and RR genotypes. Consequently, the frequency of the LEPR 223R allele was found to be significantly higher in patients group compared with controls.
###end p 61
###begin p 62
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 72 76 72 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 80 85 80 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 140 144 140 144 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 154 159 154 159 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 261 265 261 265 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 269 274 269 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 269 274 269 274 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
In this study, we investigate the prognostic significance evaluation of LEP and LEPR polymorphism by examining the potential association of LEP -2548 and LEPR exon 6 variations and the clinical response to chemotherapy induction. This evaluation indicated that LEP and LEPR polymorphisms do not have a predictive value for clinical responses to chemotherapy.
###end p 62
###begin p 63
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 33 37 33 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 41 46 41 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 97 111 97 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 97 111 97 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 220 230 220 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223R </italic>
###xml 220 230 220 230 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223R </italic></bold>
The prognostic evaluation of the LEP and LEPR genetic markers in breast carcinoma indicated that LEP (-2548) A allele is associated with a larger tumor size at diagnosis and a shorter disease-free survival, and that the LEPR 223R allele is associated with shorter overall survival, and therefore with a poor prognosis in breast carcinoma.
###end p 63
###begin p 64
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
Both functional studies and genetic analyses have highlighted the role of LEP and LEPR in cancer pathogenesis and disease progression [64-67].
###end p 64
###begin p 65
###xml 35 49 35 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 35 49 35 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 174 185 174 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR Q223R </italic>
###xml 174 185 174 185 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR Q223R </italic></bold>
###xml 250 260 250 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223R </italic>
###xml 250 260 250 260 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223R </italic></bold>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 389 399 389 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223R </italic>
###xml 389 399 389 399 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223R </italic></bold>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
Previous reports demonstrated that LEP (-2548) A allele was significantly associated with higher leptin level [55,56]. However, the relationship between leptin level and the LEPR Q223R polymorphism are conflicting. Quinton et al. have indicated that LEPR 223R allele was associated with lower circulating leptin level [68]. In contrast, Yiannakouris et al. have found that carriers of the LEPR 223R allele had significantly higher leptin level than non carriers [57].
###end p 65
###begin p 66
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 52 56 52 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 60 65 60 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 117 131 117 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 117 131 117 131 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 299 310 299 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR Q223R </italic>
###xml 299 310 299 310 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR Q223R </italic></bold>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
Several studies have shown the relationship between LEP and LEPR gene polymorphisms and human cancer [66,67,69]. The LEP (-2548) A allele, which result in high leptin secretion, was associated with increased risk of prostate cancer [66]. Recently, a study conducted on 45 patients has reported that LEPR Q223R polymorphism is not associated with an increased risk of breast cancer [69]. This result is in contrast with our findings.
###end p 66
###begin p 67
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 332 337 <span type="species:ncbi:9606">women</span>
###xml 626 634 <span type="species:ncbi:9606">patients</span>
The relationship between leptin serum level and breast cancer is still controversial. Mantzoros et al. were observed that leptin did not appear to increase the risk of pre-menopausal breast cancer in situ [70]. In addition, Petridou et al. have found no relationship between leptin serum levels and breast cancer in post-menopausal women [49]. A recent large study has demonstrated that subjects with elevated serum leptin levels displayed increased risk of developing breast cancer than those with the normal levels [52]. Furthermore, in the same study, the serum level of leptin was not associated with menopausal status in patients with mammary disease. This result along with our findings suggests that leptin increased the risk of breast cancer independently from menopausal status.
###end p 67
###begin p 68
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 248 256 <span type="species:ncbi:9606">Patients</span>
###xml 392 400 <span type="species:ncbi:9606">patients</span>
Additionnaly, in breast cancer it has been shown that a high leptin serum level is associated with reduced OVS [71]. Recently, it has been reported that the levels of expression of leptin and leptin receptor correlate with distant metastasis [47]. Patients with LEPR negative and low leptin-expressing tumors have shown an extremely good outcome, and the survival rate tended to be lower for patients with LEPR positive or high leptin-expressing tumors [47].
###end p 68
###begin p 69
###xml 241 243 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 386 388 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 525 527 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 710 712 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 847 849 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 850 852 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 1004 1006 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 157 162 <span type="species:ncbi:9606">human</span>
Some authors have demonstrated that leptin increase cell proliferation which is an essential element for tumor metastasis, through cell progression in MCF-7 human breast cancer cells with up-regulation of PKC-alpha, PPARgamma and PPARalpha [41]. Moreover, Laud et al. have suggested that leptin stimulated the proliferation of the mitogen-activated protein kinase (MAP kinase) pathway [40]. Leptin may also modulate apoptosis, since it has been reported in leukaemia cell lines that leptin acts as an inhibitor of apoptosis [72]. In addition, leptin has been shown to promote invasiveness of renal and colonic epithelial cells via the phosphatidylinositol 3'-kinase, rho-dependent, and rac-dependent cascades [43]. Others have also reported that leptin act synergistically with VEGF and fibroblast growth factor 2 (FGF-2) to promote angiogenesis [73,74]. Moreover, leptin has been shown to increase the expression of many other genes involved in angiogenesis, for example, MMP-2 and MMP-9 gene products [75].
###end p 69
###begin p 70
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
Other lines of evidence derive from studies on markers of tumoral risk that are elevated in breast cancer, that can upregulate leptin production. Factors such as TNF-alpha [76,77], IL-1alpha [78], IL-1 beta [79], estrogens [79], all raise leptin levels, promoting growth and differentiation of tumors.
###end p 70
###begin p 71
###xml 73 89 73 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) G/A </italic>
###xml 73 89 73 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) G/A </italic></bold>
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 93 98 93 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Q223R </italic>
###xml 98 104 98 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Q223R </italic></bold>
###xml 250 254 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 250 254 250 254 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 295 299 295 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 295 299 295 299 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 303 308 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 303 308 303 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
The results of the current study, which show the association between the LEP (-2548) G/A and LEPR Q223R polymorphisms and breast carcinoma susceptibility and survival, suggest that the genetic basis of the potential tumor promoter role attributed to LEP and its receptor may result from certain LEP and LEPR polymorphisms. Therefore, these polymorphisms may play a casual role in tumor development as well as in governing poor prognosis of breast carcinoma.
###end p 71
###begin title 72
Conclusion
###end title 72
###begin p 73
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 72 76 72 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP </italic></bold>
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
###xml 93 98 93 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR </italic></bold>
In conclusion, this study suggests that genetic variation in the tandem LEP and its receptor LEPR may be attractive susceptibility markers for breast carcinoma. These genetic markers represent also, prognostic variables for predicting recurrence and death from breast carcinoma.
###end p 73
###begin p 74
The role of the leptin and its receptor as genetic markers for breast cancer can be completed with other SNPs and a haplotype analysis.
###end p 74
###begin title 75
Competing interests
###end title 75
###begin p 76
The author(s) declare that they have no competing interests.
###end p 76
###begin title 77
Authors' contributions
###end title 77
###begin p 78
SK conceived of the study, conducted data analysis, and drafted the manuscript. AD-S contributed to the design and management of data. NB and S-BA provided samples and clinical information. LC conceived, designed and participated in the data analysis and interpretation of the study. AN-H contributed to reviewing the manuscript. All authors read and approved the final manuscript.
###end p 78
###begin title 79
Pre-publication history
###end title 79
###begin p 80
The pre-publication history for this paper can be accessed here:
###end p 80
###begin p 81

###end p 81
###begin title 82
Acknowledgements
###end title 82
###begin p 83
This work was supported by le Ministere de la Recherche Scientifique et de Technologie et du Developpement des Competences, by le Ministere de l'Enseignement Superieur, by le Ministere de la Sante Publique de la Republique Tunisienne.
###end p 83
###begin article-title 84
Cancer statistics, 2000
###end article-title 84
###begin article-title 85
###xml 123 128 <span type="species:ncbi:9606">women</span>
###xml 161 166 <span type="species:ncbi:9606">women</span>
Breast Cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer
###end article-title 85
###begin article-title 86
###xml 98 103 <span type="species:ncbi:9606">women</span>
###xml 136 141 <span type="species:ncbi:9606">women</span>
Breast cancer and Hormonal contraceptives: collaborative reanalysis of individual data on 53, 297 women with breast cancer and 100, 239 women without breast cancer from 54 epidemiological studies
###end article-title 86
###begin article-title 87
Breast cancer: cause and prevention
###end article-title 87
###begin article-title 88
Breast cancer epidemiology: summary and future directions
###end article-title 88
###begin article-title 89
Food, nutrition and the prevention of cancer: A global perspective
###end article-title 89
###begin article-title 90
Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study
###end article-title 90
###begin article-title 91
The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer
###end article-title 91
###begin article-title 92
Fat, energy and breast cancer
###end article-title 92
###begin article-title 93
Anthropometric predictors of breast cancer incidence and survival in a multi-ethnic cohort of female residents of Hawaii, United States
###end article-title 93
###begin article-title 94
###xml 68 71 <span type="species:ncbi:10116">rat</span>
Reduction of enhanced mammary carcinogenesis in LA/N-cp (corpulent) rat by energy restriction
###end article-title 94
###begin article-title 95
###xml 37 41 <span type="species:ncbi:10090">mice</span>
Obesity and cancer susceptibility in mice
###end article-title 95
###begin article-title 96
Genetic obesity and neoplasia
###end article-title 96
###begin article-title 97
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Accelerated appearance of chemically induced mammary carcinomas in obese yellow (Avy/A) (BALB/c x VY) F1 hybrid mice
###end article-title 97
###begin article-title 98
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
Positional cloning of the mouse obese gene and its human homologue
###end article-title 98
###begin article-title 99
###xml 12 17 <span type="species:ncbi:10090">mouse</span>
Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks
###end article-title 99
###begin article-title 100
Weight-reducing effects of the plasma protein encoded by the obese gene
###end article-title 100
###begin article-title 101
A role for leptin and its cognate receptor in hematopoiesis
###end article-title 101
###begin article-title 102
Leptin and reproduction
###end article-title 102
###begin article-title 103
Leptin the product of Ob gene, promotes angiogenesis
###end article-title 103
###begin article-title 104
Leptin regulates proinflammatory immune responses
###end article-title 104
###begin article-title 105
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human obese (OB) gene: RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of chromosome 7
###end article-title 105
###begin article-title 106
###xml 58 63 <span type="species:ncbi:9606">human</span>
Structural organization and chromosomal assignment of the human obese gene
###end article-title 106
###begin article-title 107
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human obese gene expression: Adipocyte-specific expression and regional differences in the adipose tissue
###end article-title 107
###begin article-title 108
###xml 140 144 <span type="species:ncbi:10090">mice</span>
Localisation of binding sites in the central nervous system for leptin (OB protein) in normal, obese (ob/ob), and diabetic (db/db) C57BL/6J mice
###end article-title 108
###begin article-title 109
###xml 61 67 <span type="species:ncbi:10090">murine</span>
Leptin and leptin recptor mRNA and protein expression in the murine foetus and placenta
###end article-title 109
###begin article-title 110
Expression of the functional leptin receptor mRNA in pancreatic islet and direct inhibitory action of leptin on insulin secretion
###end article-title 110
###begin article-title 111
Novel B219/OB receptor isoforms: possible role of leptin hematopoiesis and reproduction
###end article-title 111
###begin article-title 112
###xml 42 47 <span type="species:ncbi:9606">human</span>
Leptin receptor long-form signalling in a human liver cell line
###end article-title 112
###begin article-title 113
Expression of leptin receptor in lung: leptin as a growth factor
###end article-title 113
###begin article-title 114
###xml 46 51 <span type="species:ncbi:9606">human</span>
Expression of leptin receptor isoforms in the human stomach
###end article-title 114
###begin article-title 115
The leptin receptor
###end article-title 115
###begin article-title 116
###xml 86 92 <span type="species:ncbi:9606">humans</span>
No adipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans
###end article-title 116
###begin article-title 117
Leptin and leptin receptor mRNA are widely expressed in tumors of adipocytic differenciation
###end article-title 117
###begin article-title 118
The regulation of leptin gene expressioin in the C6 glioblastoma cell line
###end article-title 118
###begin article-title 119
Leptin induces endothelin-1 in endothelial cells in vitro
###end article-title 119
###begin article-title 120
###xml 39 45 <span type="species:ncbi:10090">murine</span>
Leptin stimulates the proliferation of murine myelocytic and primitive hematopoietic progenitor cells
###end article-title 120
###begin article-title 121
###xml 44 49 <span type="species:ncbi:9606">human</span>
Leptin mediates a proliferative response in human MCF7 breast cancer cells
###end article-title 121
###begin article-title 122
###xml 38 43 <span type="species:ncbi:9606">human</span>
Identification of leptin receptors in human breast cancer: Functional activity in the T47-D breast cancer cell line
###end article-title 122
###begin article-title 123
###xml 57 62 <span type="species:ncbi:9606">human</span>
Leptin and high glucose stimulate proliferation in MCF-7 human breast cancer cells: Reciprocal involvement of PKC-alpha and PPAR expression
###end article-title 123
###begin article-title 124
Leptin a growth factor in normal and malignant breast cells and for normal mammary gland development
###end article-title 124
###begin article-title 125
Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho- and rac-dependent signalling pathways
###end article-title 125
###begin article-title 126
Leptin is a growth factor for colonic epithelial cells
###end article-title 126
###begin article-title 127
###xml 64 70 <span type="species:ncbi:10090">murine</span>
Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals
###end article-title 127
###begin article-title 128
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
Rat insulinoma-derived pancreatic beta-cells express a functional leptin receptor that mediates a proliferative response
###end article-title 128
###begin article-title 129
###xml 60 65 <span type="species:ncbi:9606">human</span>
Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer
###end article-title 129
###begin article-title 130
###xml 59 64 <span type="species:ncbi:9606">human</span>
Leptin: A proliferative factor for breast cancer? Study on human ductal carcinoma
###end article-title 130
###begin article-title 131
Leptin and insulin growth factor I in relation to breast cancer (Greece)
###end article-title 131
###begin article-title 132
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer
###end article-title 132
###begin article-title 133
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Adipocytes expression and circulating levels of leptin increase in both gynaecological and breast cancer patients
###end article-title 133
###begin article-title 134
Serum levels of leptin, insulin, and lipids in relation to breast cancer in china
###end article-title 134
###begin article-title 135
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 121 126 <span type="species:ncbi:9606">human</span>
Novel polymorphisms in the 5' region of the LEP gene: Association with leptin levels and response to low-calorie diet in human obesity
###end article-title 135
###begin article-title 136
Leptin receptor gene variation and obesity; lack of association in a white British male population
###end article-title 136
###begin article-title 137
###xml 135 140 <span type="species:ncbi:9606">Girls</span>
A common Promoter Variant of the Leptin Gene Is Associated With changes in the Relationship Between Serum Leptin and Fat Mass in Obese Girls
###end article-title 137
###begin article-title 138
A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin
###end article-title 138
###begin article-title 139
The Q223R polymorphism of the leptin receptor gene is significantly associated with obesity and predicts a small percentage of body weight and body composition variability
###end article-title 139
###begin article-title 140
###xml 36 41 <span type="species:ncbi:9606">women</span>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Breast cancer detection in Tunisian women: an analysis of a hospital trial involving 729 patients
###end article-title 140
###begin article-title 141
HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in two hours: an alternative to serological DR typing in clinical practice including donor recipient matching in cadaveric transplantation
###end article-title 141
###begin article-title 142
Nonparametric estimation from incomplete observations
###end article-title 142
###begin article-title 143
###xml 90 97 <span type="species:ncbi:9606">patient</span>
Design and analysis of randomised clinical trials requiring prolonged observation of each patient
###end article-title 143
###begin article-title 144
Body fat distribution and breast cancer in the Framingham study
###end article-title 144
###begin article-title 145
Leptin induces mitogen-activated proteinkinase-dependent proliferation of C3H10T1/2 cells
###end article-title 145
###begin article-title 146
Molecular Mechanisms Involved in the Growth Stimulation of Breast Cancer Cells by Leptin
###end article-title 146
###begin article-title 147
Leptin Enhances, via AP-1, Expression of Aromatase in the MCF-7 Cell Line
###end article-title 147
###begin article-title 148
Overexpressing Leptin Genetic Polymorphism (-2548 G/A) Is Associated With Susceptibility to Prostate cancer and Risk of Advanced Disease
###end article-title 148
###begin article-title 149
Association between leptin receptor gene polymorphisms and early-onset prostate cancer
###end article-title 149
###begin article-title 150
###xml 141 146 <span type="species:ncbi:9606">woman</span>
A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian woman
###end article-title 150
###begin article-title 151
Rlationships among serum leptin, leptin receptor gene polymorphisms, and breast cancer in Korea
###end article-title 151
###begin article-title 152
Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls
###end article-title 152
###begin article-title 153
Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?
###end article-title 153
###begin article-title 154
Expression and function of leptin receptor isoforms in myeloid leukaemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities
###end article-title 154
###begin article-title 155
Biological action of leptin as an angiogenic factor
###end article-title 155
###begin article-title 156
###xml 37 42 <span type="species:ncbi:9031">chick</span>
Angiogenic activity of leptin in the chick embryo chorioallantoic membrane is in part mediated by endogenous fibroblast growth factor-2
###end article-title 156
###begin article-title 157
Potential role of leptin in angiogenesis: Leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro
###end article-title 157
###begin article-title 158
Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes
###end article-title 158
###begin article-title 159
###xml 55 61 <span type="species:ncbi:9606">humans</span>
Tumor necrosis factor increases serum leptin levels in humans
###end article-title 159
###begin article-title 160
###xml 60 66 <span type="species:ncbi:9606">humans</span>
Interleukin 1alpha increases serum leptin concentrations in humans
###end article-title 160
###begin article-title 161
###xml 79 83 <span type="species:ncbi:10116">rats</span>
Blood to brain transfer of leptin in normal and interleukin-1beta treated male rats
###end article-title 161
###begin title 162
Figures and Tables
###end title 162
###begin p 163
###xml 161 175 161 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP (-2548) A </italic>
###xml 161 175 161 175 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEP (-2548) A </italic></bold>
###xml 183 185 183 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Breast carcinoma specific overall survival (A1) and specific disease-free survival (A2) of 308 breast carcinoma patients according to the presence or absence of LEP (-2548) A allele (p denotes the log-rank test value).
###end p 163
###begin p 164
###xml 161 171 161 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR 223R </italic>
###xml 161 171 161 171 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LEPR 223R </italic></bold>
###xml 179 181 179 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Breast carcinoma specific overall survival (B1) and specific disease-free survival (B2) of 308 breast carcinoma patients according to the presence or absence of LEPR 223R allele (p denotes the log-rank test value).
###end p 164
###begin p 165
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Treatment description of the 308 patients with Breast Carcinoma
###end p 165
###begin p 166
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G/A </italic>
###xml 24 35 24 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR Q223R </italic>
###xml 85 93 <span type="species:ncbi:9606">Patients</span>
The LEP (-2548) G/A and LEPR Q223R Genotype distributions in Control Subjects and in Patients with Breast Carcinoma.
###end p 166
###begin p 167
###xml 48 50 46 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 110 111 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 193 194 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f</italic>
###xml 142 149 <span type="species:ncbi:9606">patient</span>
OR, odds ratio; CI, confidence interval. The chi2 test was used to determine whether significant differences (P-value) were observed when the patient group was compared with the control group. f, frequencies.
###end p 167
###begin p 168
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEP </italic>
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEPR </italic>
Genotype frequencies of LEP and LEPR polymorphisms in relation to pathological indices of breast cancer severity.
###end p 168
###begin p 169
###xml 48 50 46 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 110 111 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 193 194 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f</italic>
###xml 142 149 <span type="species:ncbi:9606">patient</span>
OR, odds ratio; CI, confidence interval. The chi2 test was used to determine whether significant differences (P-value) were observed when the patient group was compared with the control group. f, frequencies.
###end p 169

